Vertidiag is a biotechnology company specializing in vestibular disorders.
Vertidiag develops proprietary solutions against these conditions and also offers its technological platform for contract research activities.
Vertidiag is one of the leaders in the fight against vertigo.
Vestibular disorders are a public health issue
Why Vertidiag ?
No effective and well-tolerated treatment for vertigo is currently available on the market.
Thanks to its unique assets, Vertidiag is one of the leader in innovation against vestibular pathologies.
Nicolas is Vertidiag's CEO. He is a former student of Sciences Po Paris, and is currently a doctoral researcher in economics at the London School of Economics, UK. He has received a scholarship from the Economic and Social Research Council.
Christian Chabbert, PhD, HDR, is scientific advisor. Christian leads the team Physiopathology and Vestibular Disorders Therapy (UMR7260 CNRS-AMU), and founder of the GDR Vertige, a federative group of academics and clinicians involved in vertigo research.
Michel Kaczorek is member of the Board. After 22 in research, he founded Synt:em SA, and then accompanied many start-ups as co-founder or director. He is a member of Eurobiomed and SATT AxLR's steering and investment committees.
Brahim Tighilet, PhD, HDR is a scientific advisor. He currently is Senior Lecturer at Aix-Marseille Université. His expertise in the field of vestibular compensation is internationally recognised, by academics and industrials alike.